Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma Full Text
Clinical Cancer Research, 05/16/2012
Clinical Article
Turley RS et al. – Systemic treatment with bevacizumab before regional chemotherapy increases delivery of melphalan (LPAM) to tumor cells and represents a novel way to augment response to regional therapy for advanced extremity melanoma.



